The impact of GnRH agonists on ischemic heart disease has not been established, but some authors report an increased risk of cardiovascular toxicity after treatment with GnRH agonists, especially in men with prostate cancer [113,114], whereas it has not been demonstrated in women with BC. This evidence concerns the gene GNRH1 and prostate carcinoma.